Adma Biologics reported $684.21M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Adma Biologics USD 684.21M 19.03M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 955.58M 87.59M Jun/2026
Omeros USD 200.57M 34.59M Jun/2025
Takeda JPY 15.66T 210.16B Jun/2026